查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1474872

鮑氏不動桿菌桿菌治療藥物市場規模、佔有率、趨勢分析報告：依藥物類別、給藥途徑、地區、細分市場預測，2024-2030年

Acinetobacter Pneumonia Therapeutics Market Size, Share & Trends Analysis Report By Drug Class (Xacduro, Polymyxins, Cephalosporins, Carbapenems), By Route Of Administration (Oral, Parenteral), By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

鮑氏不動桿菌肺炎治療藥物市場成長與趨勢：

根據Grand View Research, Inc.最新報告，預計到2030年，全球鮑氏不動桿菌肺炎治療市場規模將達47,096萬美元，2024年至2030年複合年成長率為6.70%。

有幾個因素正在推動市場成長，包括不鮑氏不動桿菌感染疾病的高發生率、抗生素抗藥性的上升、廣泛的研究和開發、有利的政府舉措和資金以及抗藥性的上升。鮑曼不動桿菌是引起住院病人醫院感染的主要病原菌。這種病原體會導致人工呼吸器相關性肺炎和血流感染。據報道，該菌株具有多重抗藥性，且傳播速度極快。

這種生物體的治療很困難，並且由於鮑曼不動桿菌的多重抗藥性而受到阻礙。聯合治療是此類感染疾病最常使用的治療方法。治療鮑氏不動桿菌肺炎的第一線藥物包括B-內醯胺類抗生素、頭孢菌素類抗生素、碳青黴烯類抗生素、Fluoroquinolones抗生素、舒巴坦類抗生素、磺胺類藥物抗生素等。根據嚴重程度，這些藥物可以用作單一藥物或聯合治療的一部分。如果第一線藥物無效，則給予二線抗生素，如Aminoglycosides、多粘菌素類、四環黴素、Glycylcycline。這些藥物因其副作用而被視為二線藥物。

鮑氏不動桿菌肺炎治療藥物市場報告亮點

  • 2023 年，頭孢菌素類藥物類別佔據最大收益佔有率。頭孢他啶用作第一線藥物，頭孢地羅用作二線藥物。
  • 此外，在舒巴坦領域，新推出的 Zakuduro 預計在預測期內將以顯著的複合年成長率成長。
  • 根據給藥途徑，注射給藥領域在 2023 年佔據了最大的收益佔有率。透過靜脈注射快速直接輸送抗生素可確保快速吸收和有效性，使其成為治療嚴重感染疾病的首選方法。
  • Zacduro（注射舒巴坦；注射杜洛巴坦）、多粘菌素（粘菌素）、碳青黴烯類和Aminoglycosides是一些用於治療不鮑氏不動桿菌肺炎的胃腸外給藥藥物。
  • 2023年，北美地區佔37.31%。這是由於先進的醫療基礎設施、高度的意識和廣泛的臨床試驗研究活動。
  • 該地區鮑氏不動桿菌肺炎盛行率較高，疾病診治意識較高。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第3章鮑氏不動桿菌肺炎治療藥物市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場推動要素分析
    • 市場限制因素分析
  • 鮑氏不動桿菌肺炎治療藥物市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析
    • 價格分析
    • 管道分析

第4章鮑氏不動桿菌肺炎治療藥物市場：藥物類別估計與趨勢分析

  • 全球鮑氏不動桿菌肺炎治療藥物市場：藥物類別細分儀表板
  • 全球鮑氏不動桿菌肺炎治療藥物市場：藥物類別波動分析
  • 2018-2030年全球鮑氏不動桿菌肺炎治療藥物市場規模及趨勢分析（依藥物類別）
  • 頭孢菌素
  • Fluoroquinolones
  • Glycylcycline
  • 碳青黴烯類
  • BETA-內醯胺類抗生素
  • 舒巴坦
  • Aminoglycosides
  • 多粘菌素
  • 四環黴素
  • 磺胺類藥物
  • 其他

第5章鮑氏不動桿菌肺炎治療藥物市場：給藥途徑估算及趨勢分析

  • 全球鮑氏不動桿菌肺炎治療藥物市場：給藥途徑細分儀表板
  • 全球鮑氏不動桿菌肺炎治療藥物市場：給藥途徑變化分析
  • 2018-2030年全球鮑氏不動桿菌肺炎治療藥物市場規模及趨勢分析（依給藥途徑）
  • 胃腸外的
  • 口服
  • 其他

第6章鮑氏不動桿菌肺炎治療藥物市場：區域估計與趨勢分析

  • 區域市場儀表板
  • 市場規模/預測、趨勢分析，2018-2030
  • 北美洲
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東/非洲

第7章 競爭格局

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司/競爭對手分類
  • 供應商情況
    • Pfizer Inc.
    • Merck &Co., Inc.
    • GlaxoSmithKline plc（GSK）
    • AstraZeneca plc
    • Novartis AG
    • Johnson &Johnson
    • Sanofi SA
    • Bayer AG
    • Basilea Pharmaceutica
Product Code: GVR-4-68040-252-2

Acinetobacter Pneumonia Therapeutics Market Growth & Trends:

The global acinetobacter pneumonia therapeutics market size is expected to reach USD 470.96 million by 2030, registering a CAGR of 6.70% from 2024 to 2030, according to a new report by Grand View Research, Inc. Several factors are responsible for driving market growth including a high incidence of acinetobacter infections, rising antibiotic resistance, extensive R&D, and favorable government initiatives & funding, and rising drug resistance. Acinetobacter baumannii is a major pathogen responsible for causing hospital-acquired infections in hospitalized patients. The pathogen causes ventilator-associated pneumonia and bloodstream infection. This strain of microorganisms has been reported to be multidrug-resistant and can spread extremely fast.

The treatment of this microorganism can be challenging and is hampered due to the multidrug resistance of the Acinetobacter baumannii. Combination therapy is the most widely used treatment for these kinds of infections. The first line of treatment for acinetobacter pneumonia includes drug classes, such as B-lactam antibiotics, cephalosporins, carbapenem, fluoroquinolone, sulbactam, and sulfonamide. The therapeutics are used in monotherapy or as part of combination therapy depending on the severity of illness. In case the first-line treatment is not effective, second-line antibiotics are administered, which include drug classes, such as aminoglycoside, polymyxins, tetracycline, and glycylcycline. These drugs are considered second-line due to their adverse effects.

Acinetobacter Pneumonia Therapeutics Market Report Highlights:

  • The cephalosporins drug class segment accounted for the largest revenue share in 2023. Ceftazidime is used as a first-line treatment; cefiderocol is used as second-linene treatment for the disease
  • In addition, the newly launched Xacduro under the sulbactam segment is expected to grow at a significant CAGR during the forecast period
  • Based on the route of administration, the parenteral segment accounted for the largest revenue share in 2023. The rapid and direct delivery of antibiotics via the IV route ensures rapid absorption and efficacy and makes it the preferred method for treating severe infections
  • Xacduro (sulbactam for injection; durlobactam for injection), polymyxins (colistin), carbapenems, and aminoglycosides are some of the drugs administered parenterally for the treatment of acinetobacter pneumonia
  • In 2023, North America dominated with a share of 37.31% owing to the advanced healthcare infrastructure, high awareness levels, and extensive research activities for clinical trials
  • The region has a high prevalence of acinetobacter pneumonia along with high awareness about disease diagnosis and treatment

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Drug Class
    • 1.2.2. Route of Administration
  • 1.3. Regional scope
  • 1.4. Estimates and forecasts timeline
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased database
    • 1.6.2. GVR's internal database
    • 1.6.3. Secondary sources
    • 1.6.4. Primary research
    • 1.6.5. Details of primary research
      • 1.6.5.1. Data for primary interviews in North America
      • 1.6.5.2. Data for primary interviews in Europe
      • 1.6.5.3. Data for primary interviews in Asia Pacific
      • 1.6.5.4. Data for primary interviews in Latin America
      • 1.6.5.5. Data for Primary interviews in MEA
  • 1.7. Information or Data Analysis
    • 1.7.1. Data analysis models
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity flow analysis (Model 1)
    • 1.9.2. Approach 1: Commodity flow approach
    • 1.9.3. Volume price analysis (Model 2)
    • 1.9.4. Approach 2: Volume price analysis
  • 1.10. List of Secondary Sources
  • 1.11. List of Primary Sources
  • 1.12. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Drug class outlook
    • 2.2.2. Route of administration outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Acinetobacter Pneumonia Therapeutics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing incidence of Acinetobacter infections
      • 3.2.1.2. Increasing prevalence of antibiotic resistance
      • 3.2.1.3. Increasing research & development and fundings
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Side effects and adverse reactions
      • 3.2.2.2. High cost of drug development
  • 3.3. Acinetobacter Pneumonia Therapeutics Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
    • 3.3.3. Pricing Analysis
    • 3.3.4. Pipeline Analysis

Chapter 4. Acinetobacter Pneumonia Therapeutics Market: Drug Class Estimates & Trend Analysis

  • 4.1. Global Acinetobacter Pneumonia Therapeutics Market: Drug Class Segment Dashboard
  • 4.2. Global Acinetobacter Pneumonia Therapeutics Market: Drug Class Movement Analysis
  • 4.3. Global Acinetobacter Pneumonia Therapeutics Market Size & Trend Analysis, by Drug Class, 2018 to 2030 (USD Million)
  • 4.4. Cephalosporins
    • 4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Fluoroquinolone
    • 4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6. Glycylcycline
    • 4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7. Carbapenem
    • 4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.8. B-Lactam antibiotics
    • 4.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.9. Sulbactam
    • 4.9.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.10. Aminoglycoside
    • 4.10.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.11. Polymyxins
    • 4.11.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.12. Tetracycline
    • 4.12.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.13. Sulfonamide
    • 4.13.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.14. Other
    • 4.14.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Acinetobacter Pneumonia Therapeutics Market: Route of Administration Estimates & Trend Analysis

  • 5.1. Global Acinetobacter Pneumonia Therapeutics Market: Route of Administration Segment Dashboard
  • 5.2. Global Acinetobacter Pneumonia Therapeutics Market: Route of Administration Movement Analysis
  • 5.3. Global Acinetobacter Pneumonia Therapeutics Market Size & Trend Analysis, by Route of Administration, 2018 to 2030 (USD Million)
  • 5.4. Parenteral
    • 5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Oral
    • 5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6. Other
    • 5.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Acinetobacter Pneumonia Therapeutics Market: Regional Estimates & Trend Analysis by

  • 6.1. Regional Market Dashboard
  • 6.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 6.3. North America
    • 6.3.1. U.S.
      • 6.3.1.1. Key country dynamics
      • 6.3.1.2. Regulatory framework/ reimbursement structure
      • 6.3.1.3. Competitive scenario
      • 6.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.3.2. Canada
      • 6.3.2.1. Key country dynamics
      • 6.3.2.2. Regulatory framework/ reimbursement structure
      • 6.3.2.3. Competitive scenario
      • 6.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4. Europe
    • 6.4.1. UK
      • 6.4.1.1. Key country dynamics
      • 6.4.1.2. Regulatory framework/ reimbursement structure
      • 6.4.1.3. Competitive scenario
      • 6.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.2. Germany
      • 6.4.2.1. Key country dynamics
      • 6.4.2.2. Regulatory framework/ reimbursement structure
      • 6.4.2.3. Competitive scenario
      • 6.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.3. France
      • 6.4.3.1. Key country dynamics
      • 6.4.3.2. Regulatory framework/ reimbursement structure
      • 6.4.3.3. Competitive scenario
      • 6.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.4. Italy
      • 6.4.4.1. Key country dynamics
      • 6.4.4.2. Regulatory framework/ reimbursement structure
      • 6.4.4.3. Competitive scenario
      • 6.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.5. Spain
      • 6.4.5.1. Key country dynamics
      • 6.4.5.2. Regulatory framework/ reimbursement structure
      • 6.4.5.3. Competitive scenario
      • 6.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.6. Norway
      • 6.4.6.1. Key country dynamics
      • 6.4.6.2. Regulatory framework/ reimbursement structure
      • 6.4.6.3. Competitive scenario
      • 6.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.7. Sweden
      • 6.4.7.1. Key country dynamics
      • 6.4.7.2. Regulatory framework/ reimbursement structure
      • 6.4.7.3. Competitive scenario
      • 6.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.8. Denmark
      • 6.4.8.1. Key country dynamics
      • 6.4.8.2. Regulatory framework/ reimbursement structure
      • 6.4.8.3. Competitive scenario
      • 6.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Asia Pacific
    • 6.5.1. Japan
      • 6.5.1.1. Key country dynamics
      • 6.5.1.2. Regulatory framework/ reimbursement structure
      • 6.5.1.3. Competitive scenario
      • 6.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.2. China
      • 6.5.2.1. Key country dynamics
      • 6.5.2.2. Regulatory framework/ reimbursement structure
      • 6.5.2.3. Competitive scenario
      • 6.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.3. India
      • 6.5.3.1. Key country dynamics
      • 6.5.3.2. Regulatory framework/ reimbursement structure
      • 6.5.3.3. Competitive scenario
      • 6.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.4. Australia
      • 6.5.4.1. Key country dynamics
      • 6.5.4.2. Regulatory framework/ reimbursement structure
      • 6.5.4.3. Competitive scenario
      • 6.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.5. South Korea
      • 6.5.5.1. Key country dynamics
      • 6.5.5.2. Regulatory framework/ reimbursement structure
      • 6.5.5.3. Competitive scenario
      • 6.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.6. Thailand
      • 6.5.6.1. Key country dynamics
      • 6.5.6.2. Regulatory framework/ reimbursement structure
      • 6.5.6.3. Competitive scenario
      • 6.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Latin America
    • 6.6.1. Brazil
      • 6.6.1.1. Key country dynamics
      • 6.6.1.2. Regulatory framework/ reimbursement structure
      • 6.6.1.3. Competitive scenario
      • 6.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.2. Mexico
      • 6.6.2.1. Key country dynamics
      • 6.6.2.2. Regulatory framework/ reimbursement structure
      • 6.6.2.3. Competitive scenario
      • 6.6.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.3. Argentina
      • 6.6.3.1. Key country dynamics
      • 6.6.3.2. Regulatory framework/ reimbursement structure
      • 6.6.3.3. Competitive scenario
      • 6.6.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7. MEA
    • 6.7.1. South Africa
      • 6.7.1.1. Key country dynamics
      • 6.7.1.2. Regulatory framework/ reimbursement structure
      • 6.7.1.3. Competitive scenario
      • 6.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.2. Saudi Arabia
      • 6.7.2.1. Key country dynamics
      • 6.7.2.2. Regulatory framework/ reimbursement structure
      • 6.7.2.3. Competitive scenario
      • 6.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.3. UAE
      • 6.7.3.1. Key country dynamics
      • 6.7.3.2. Regulatory framework/ reimbursement structure
      • 6.7.3.3. Competitive scenario
      • 6.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.4. Kuwait
      • 6.7.4.1. Key country dynamics
      • 6.7.4.2. Regulatory framework/ reimbursement structure
      • 6.7.4.3. Competitive scenario
      • 6.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/Competition Categorization
  • 7.3. Vendor Landscape
    • 7.3.1. List of key distributors and channel partners
    • 7.3.2. Key customers
    • 7.3.3. Key company market share analysis, 2023
    • 7.3.4. Pfizer Inc.
      • 7.3.4.1. Company overview
      • 7.3.4.2. Financial performance
      • 7.3.4.3. Product benchmarking
      • 7.3.4.4. Strategic initiatives
    • 7.3.5. Merck & Co., Inc.
      • 7.3.5.1. Company overview
      • 7.3.5.2. Financial performance
      • 7.3.5.3. Product benchmarking
      • 7.3.5.4. Strategic initiatives
    • 7.3.6. GlaxoSmithKline plc (GSK)
      • 7.3.6.1. Company overview
      • 7.3.6.2. Financial performance
      • 7.3.6.3. Product benchmarking
      • 7.3.6.4. Strategic initiatives
    • 7.3.7. AstraZeneca plc
      • 7.3.7.1. Company overview
      • 7.3.7.2. Financial performance
      • 7.3.7.3. Product benchmarking
      • 7.3.7.4. Strategic initiatives
    • 7.3.8. Novartis AG
      • 7.3.8.1. Company overview
      • 7.3.8.2. Financial performance
      • 7.3.8.3. Product benchmarking
      • 7.3.8.4. Strategic initiatives
    • 7.3.9. Johnson & Johnson
      • 7.3.9.1. Company overview
      • 7.3.9.2. Financial performance
      • 7.3.9.3. Product benchmarking
      • 7.3.9.4. Strategic initiatives
    • 7.3.10. Sanofi S.A.
      • 7.3.10.1. Company overview
      • 7.3.10.2. Financial performance
      • 7.3.10.3. Product benchmarking
      • 7.3.10.4. Strategic initiatives
    • 7.3.11. Bayer AG
      • 7.3.11.1. Company overview
      • 7.3.11.2. Financial performance
      • 7.3.11.3. Product benchmarking
      • 7.3.11.4. Strategic initiatives
    • 7.3.12. Basilea Pharmaceutica
      • 7.3.12.1. Company overview
      • 7.3.12.2. Financial performance
      • 7.3.12.3. Product benchmarking
      • 7.3.12.4. Strategic initiatives

List of Tables

  • Table 1 List of key distributors and channel partners
  • Table 2 List of key emerging companies'/technology disruptors/innovators
  • Table 3 North America Acinetobacter Pneumonia Therapeutics Market, by country, 2018 - 2030 (USD Million)
  • Table 4 North America Acinetobacter Pneumonia Therapeutics Market, by Drug class, 2018 - 2030 (USD Million)
  • Table 5 North America Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 6 U.S. Acinetobacter Pneumonia Therapeutics Market, by Drug class, 2018 - 2030 (USD Million)
  • Table 7 U.S. Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 8 Canada Acinetobacter Pneumonia Therapeutics Market, by Drug class, 2018 - 2030 (USD Million)
  • Table 9 Canada Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 10 Europe Acinetobacter Pneumonia Therapeutics Market, by country, 2018 - 2030 (USD Million)
  • Table 11 Europe Acinetobacter Pneumonia Therapeutics Market, by Drug class, 2018 - 2030 (USD Million)
  • Table 12 Europe Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 13 Germany Acinetobacter Pneumonia Therapeutics Market, by Drug class, 2018 - 2030 (USD Million)
  • Table 14 Germany Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 15 UK Acinetobacter Pneumonia Therapeutics Market, by Drug class, 2018 - 2030 (USD Million)
  • Table 16 UK Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 17 France Acinetobacter Pneumonia Therapeutics Market, by Drug class, 2018 - 2030 (USD Million)
  • Table 18 France Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 19 Italy Acinetobacter Pneumonia Therapeutics Market, by Drug class, 2018 - 2030 (USD Million)
  • Table 20 Italy Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million
  • Table 21 Spain Acinetobacter Pneumonia Therapeutics Market, by Drug class, 2018 - 2030 (USD Million)
  • Table 22 Spain Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 23 Denmark Acinetobacter Pneumonia Therapeutics Market, by Drug class, 2018 - 2030 (USD Million)
  • Table 24 Denmark Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 25 Sweden Acinetobacter Pneumonia Therapeutics Market, by Drug class, 2018 - 2030 (USD Million)
  • Table 26 Sweden Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 27 Norway Acinetobacter Pneumonia Therapeutics Market, by Drug class, 2018 - 2030 (USD Million)
  • Table 28 Norway Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 29 Asia Pacific Acinetobacter Pneumonia Therapeutics Market, by country, 2018 - 2030 (USD Million)
  • Table 30 Asia Pacific Acinetobacter Pneumonia Therapeutics Market, by Drug class, 2018 - 2030 (USD Million)
  • Table 31 Asia Pacific Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 32 Japan Acinetobacter Pneumonia Therapeutics Market, by Drug class, 2018 - 2030 (USD Million)
  • Table 33 Japan Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 34 China Acinetobacter Pneumonia Therapeutics Market, by Drug class, 2018 - 2030 (USD Million)
  • Table 35 China Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 36 India Acinetobacter Pneumonia Therapeutics Market, by Drug class, 2018 - 2030 (USD Million)
  • Table 37 India Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 38 Australia Acinetobacter Pneumonia Therapeutics Market, by Drug class, 2018 - 2030 (USD Million)
  • Table 39 Australia Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 40 South Korea Acinetobacter Pneumonia Therapeutics Market, by Drug class, 2018 - 2030 (USD Million)
  • Table 41 South Korea Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 42 Thailand Acinetobacter Pneumonia Therapeutics Market, by Drug class, 2018 - 2030 (USD Million)
  • Table 43 Thailand Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 44 Latin America Acinetobacter Pneumonia Therapeutics Market, by country, 2018 - 2030 (USD Million)
  • Table 45 Latin America Acinetobacter Pneumonia Therapeutics Market, by Drug class, 2018 - 2030 (USD Million)
  • Table 46 Latin America Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million
  • Table 47 Brazil Acinetobacter Pneumonia Therapeutics Market, by Drug class, 2018 - 2030 (USD Million)
  • Table 48 Brazil Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 49 Mexico Acinetobacter Pneumonia Therapeutics Market, by Drug class, 2018 - 2030 (USD Million)
  • Table 50 Mexico Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 51 Argentina Acinetobacter Pneumonia Therapeutics Market, by Drug class, 2018 - 2030 (USD Million)
  • Table 52 Argentina Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 53 MEA Acinetobacter Pneumonia Therapeutics Market, by country, 2018 - 2030 (USD Million)
  • Table 54 MEA Acinetobacter Pneumonia Therapeutics Market, by Drug class, 2018 - 2030 (USD Million)
  • Table 55 MEA Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 56 South Africa Acinetobacter Pneumonia Therapeutics Market, by Drug class, 2018 - 2030 (USD Million)
  • Table 57 South Africa Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 58 Saudi Arabia Acinetobacter Pneumonia Therapeutics Market, by Drug class, 2018 - 2030 (USD Million)
  • Table 59 Saudi Arabia Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 60 UAE Acinetobacter Pneumonia Therapeutics Market, by Drug class, 2018 - 2030 (USD Million)
  • Table 61 UAE Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 62 Kuwait Acinetobacter Pneumonia Therapeutics Market, by Drug class, 2018 - 2030 (USD Million)
  • Table 63 Kuwait Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Acinetobacter pneumonia therapeutics market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value chain-based sizing & forecasting
  • Fig. 7 QFD modelling for market share assessment
  • Fig. 8 Acinetobacter pneumonia therapeutics market snapshot (2023)
  • Fig. 9 Acinetobacter pneumonia therapeutics market: Segment snapshot (2023)
  • Fig. 10 Competitive Insights (2023)
  • Fig. 11 Parent market outlook
  • Fig. 12 Related/ancillary market outlook
  • Fig. 13 Penetration and growth prospect mapping
  • Fig. 14 Acinetobacter Pneumonia Therapeutics Market driver impact
  • Fig. 15 Acinetobacter Pneumonia Therapeutics Market restraint impact
  • Fig. 16 Porter's Five Forces Analysis
  • Fig. 17 SWOT Analysis, By Factor (Political & legal Economic and technological)
  • Fig. 18 Strategic alliance analysis
  • Fig. 19 Recent developments & impact analysis, by key market participants
  • Fig. 20 Key company market share analysis, 2023
  • Fig. 21 Company market position analysis
  • Fig. 22 Definition and scope, by drug class
  • Fig. 23 Drug class market share analysis, 2023 & 2030
  • Fig. 24 Segment dashboard
  • Fig. 25 Global Acinetobacter Pneumonia Therapeutics Market, by drug class, 2018 - 2030 (USD Million)
  • Fig. 26 Cephalosporins market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 27 Nonsteroidal Anti-inflammatory Drugs market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 28 Naproxen market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 29 Fluoroquinolone market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 30 Glycylcycline market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 31 Carbapenem market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 32 B-Lactam antibiotics market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 33 Sulbactam market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 34 Aminoglycoside market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 35 Polymyxins market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 36 Other NSAIDs market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 37 Tetracycline market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 38 Sulfonamide market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 39 Others market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 40 Definition and scope, by Route of Administration
  • Fig. 41 Anatomy market share analysis, 2023 & 2030
  • Fig. 42 Segment dashboard
  • Fig. 43 Global Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Fig. 44 Parenteral market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 45 Oral market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 46 Other route market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 47 North America market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 48 U.S. market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 49 Canada market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 50 Europe market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 51 UK market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 52 Germany market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 53 Spain market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 54 France market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 55 Italy market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 56 Sweden market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 57 Denmark market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 58 Norway market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 59 Asia Pacific market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 60 China market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 61 Japan market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 62 India market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 63 Australia market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 64 South Korea market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 65 Thailand market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 66 Latin America market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 67 Brazil market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 68 Mexico market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 69 Argentina market size, & forecasts and trend analysis, 2018 to 2030 (USD Million))
  • Fig. 70 Middle East and Africa market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 71 South Africa market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 72 Saudi Arabia market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 73 UAE market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
  • Fig. 74 Kuwait market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)